|
Media Releases |
Financial Reports |
Presen-tations |
|
27.11.2002
|
|
|
|
| Basel - Lonza announced today that a company sponsored clinical study conducted at the University of Leipzig (Germany), has found that supplementation with L-Carnitine Crystalline significantly increases fatty acid oxidation in healthy adults. This study is significant because it is the first investigation to conclusively show that oral L-Carnitine Crystalline supplementation stimulates in vivo long chain fatty acid metabolism. Results of this study have been published in Metabolism Vol 51, No 11: 1389-91, 2002. |
Clinical Study Published in Metabolism Shows Lonza's L-CARNIPURE® L-Carnitine Crystalline increases Fat Oxidation in Healthy Adults
|
 |
L-Carnitine, a vitamin-like nutrient, occurs naturally in the human body and is essential for turning fat into energy. Due to clinical research, L-Carnitine is already a popular dietary supplement among physically active people who supplement with this nutrient to help with post-exercise recovery. Extensive scientific research indicates that
L-Carnitine promotes cardiovascular health and studies also suggest that L-Carnitine may be useful as part of a weight management program.
The present clinical study was conducted under guidance of Dr. Detlef Müller. The study investigated the effects of oral L-CARNIPURE® L-Carnitine Crystalline supplementation on in vivo long chain fatty acid oxidation by measuring 1-[13C] palmitic acid oxidation in healthy adults before and after L-CARNIPURE® L-Carnitine Crystalline supplementation (3x1 g/d for 10 days). "We observed a significant increase in 13CO2 exhalation, thereby indicating a significant increase in fat oxidation in healthy adults," said Dr. Müller.
Dr. Andrea O. Schaffhauser, Manager Scientific Affairs & Market Development, Lonza Ltd., commented, "part of this study has been presented at the Experimental Biology Meeting in Orlando, Florida, 2001. We at Lonza are pleased to now be presenting the full paper of this breakthrough data to the scientific community." According to Dr. Müller, "this study is important to all people who exercise, those who undergo a weight management program and those who have a high energy demand".
Lonza Group is the world's largest manufacturer of L-Carnitine and is the only manufacturer that guarantees 100% pure L-Carnitine, completely free from harmful
D-Carnitine. L-CARNIPURE® L-Carnitine Crystalline contains 100% L-Carnitine, while L-CARNIPURE® L -Carnitine L-Tartrate (U.S. Patent 5,073,376 and other international patents) consists of 68% L-Carnitine and 32% L-tartaric acid. Most recently, CARNIPURE® L-Carnitine Crystalline and L-Carnitine L-Tartrate have been self affirmed as GRAS (Generally Recognized as Safe). Being crystalline, white, water-soluble and heat stable, both products are ideal for use in various food and drink applications. In addition, L-Carnitine L-Tartrate is non-hygroscopic, odorless and has a pleasant citrus taste and excellent flowability. Both products are kosher certified. Further details are available at www.carnitine.com.
Lonza Group is a Life Sciences driven chemical company headquartered in Switzerland, with sales of CHF 2.5 billion in 2001 and operating 21 production and R&D facilities in 9 countries. It employs 6 400 people worldwide and is the leading supplier of active chemical ingredients, intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. It also offers a broad catalogue of organic intermediates for a wide range of applications such as pharmaceuticals, agrochemicals, vitamins, food and feedstuff, dyes and pigments, adhesives and fragrances. Furthermore the Group manufactures specialty biocides and oleochemicals and develops and produces specific polymer intermediates, unsaturated polyester-resins, compounds and composites. For more information on Lonza Group please visit the company's website at www.lonzagroup.com.
For further information please contact:
Dr. Walter Eschenmoser
Communications/Investor Relations
Tel +41 61 316 8363
Fax +41 61 316 8220
walter.eschenmoser@lonzagroup.com
Dr. Andrea O. Schaffhauser
Manager Scientific Affairs & Market Development
Lonza Ltd
Tel +41 61 316 85 47
Fax +41 61 316 84 46
andrea.schaffhauser@lonzagroup.com
|
|
|
